Clinerion, Medexprim combine clinical and imaging data for researchMarch 5, 2021
Clinerion and Medexprim will set up a joint offering which allows access to de-identified, enriched, longitudinal data points derived from complex medical data sets, which combine electronic health records and their corresponding clinical images, to improve research and help patients receive better care.
This collaboration will accelerate and expand Clinerion’s and Medexprim’s networks of hospital partners and accelerate the implementation of a clinical data warehouse globally accessible via a proprietary cloud.
Clinerion is the worldwide leader in medical data informatics, radically improving efficiency in patient search and identification, increasing effectiveness in clinical research and accelerating the process of drug development to ensure an earlier availability of medicines.
Medexprim, the European expert in generating regulatory-grade datasets of aggregated images and clinical data, builds bridges between hospitals and biopharmaceutical companies to accelerate clinical research, and helps biopharmaceutical companies access specific datasets and design more successful, cost effective and faster clinical trials.
The value of imaging data is recognized for its high clinical utility and value in the end-to-end evidence management process, notably in oncology, which is the top therapeutic area for clinical trials. Barış Erdoğan, CEO of Clinerion, says: “We are delighted to have partnered with Medexprim as we see a tremendous value in associating our access to the millions of electronic health records of our patients with their associated clinical images. We are keen to continue providing context to the pharmaceutical industry on disease development, tumor stages and rare diseases, and deliver high resolution information resulting from these two data classes. Ultimately, Clinerion is continuing to fulfil its mission of enabling a more granular patient data access for pre-screening, site selection and trial design, as well as providing much richer disease information to the clinical value chain.”
Romain Cazavan, CEO of Medexprim, says: “We are more than happy to announce our partnership with Clinerion. Clinerion’s and Medexprim’s complementary expertise will enable more European university hospitals to leverage their Real-World data and will accelerate the implementation of a clinical data warehouse in the service of clinical research and the well-being of patients. Medical imaging plays an instrumental role in clinical research: imaging is a non-invasive tool, it allows screening and stratification of patients, can reduce study budget and drug development time and accelerate regulatory approvals. Medexprim specializes in extracting complex datasets composed of clinical data, images, biology and genomics based on retrospective data. We aim to create multicentric and multiomics data lakes per disease, develop imaging biomarkers to diagnose and evaluate treatment response, introduce some biostatistics methodology to identify new patients to be included in clinical research studies but also to build synthetic control arms.”